Nuveen
FHTX icon

Nuveen’s Foghorn Therapeutics FHTX Stock Holding History

Nuveen’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Buy
65,039
+14,661
+29% +$65.1K ﹤0.01% 3484
2026
Q1 		$241K Buy
50,378
+245
+0.5% +$1.34K ﹤0.01% 3056
2025
Q4 		$271K Hold
50,133
– – ﹤0.01% 3072
2025
Q3 		$245K Hold
50,133
– – ﹤0.01% 3104
2025
Q2 		$236K Sell
50,133
-10,305
-17% -$43.1K ﹤0.01% 3118
2025
Q1 		$221K Hold
60,438
– – ﹤0.01% 3115
2024
Q4 		$285K Hold
60,438
– – ﹤0.01% 3138
2024
Q3 		$563K Sell
60,438
-7,428
-11% -$53.8K ﹤0.01% 2976
2024
Q2 		$390K Buy
67,866
+13,903
+26% +$82.8K ﹤0.01% 3074
2024
Q1 		$362K Hold
53,963
– – ﹤0.01% 3060
2023
Q4 		$348K Buy
53,963
+483
+0.9% +$2.08K ﹤0.01% 3113
2023
Q3 		$267K Hold
53,480
– – ﹤0.01% 2986
2023
Q2 		$376K Hold
53,480
– – ﹤0.01% 2983
2023
Q1 		$332K Sell
53,480
-483
-0.9% -$3.16K ﹤0.01% 2894
2022
Q4 		$345K Sell
53,963
-3,090
-5% -$23.3K ﹤0.01% 2961
2022
Q3 		$490K Sell
57,053
-2,551
-4% -$32.8K ﹤0.01% 2963
2022
Q2 		$811K Sell
59,604
-53,270
-47% -$687K ﹤0.01% 2882
2022
Q1 		$1.52M Buy
112,874
+65,887
+140% +$904K ﹤0.01% 2639
2021
Q4 		$837K Sell
46,987
-6,587
-12% -$94.7K ﹤0.01% 2914
2021
Q3 		$709K Sell
53,574
-2,836
-5% -$31.4K ﹤0.01% 3098
2021
Q2 		$602K Buy
56,410
+44,603
+378% +$486K ﹤0.01% 3140
2021
Q1 		$156K Hold
11,807
– – ﹤0.01% 3258
2020
Q4 		$239K Buy
+11,807
New +$226K ﹤0.01% 3177

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Nuveen's FHTX Position: Q2 2026 in Review

Nuveen increased its Foghorn Therapeutics (FHTX) stake by 29% in Q2 2026, buying an estimated $65.1K and bringing the position to 65,039 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #3484.

Nuveen first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $1.52M in Q1 2022. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Nuveen held 65,039 shares of Foghorn Therapeutics worth $317K as of Q2 2026.
  • Nuveen bought 14,661 Foghorn Therapeutics shares in Q2 2026, an estimated $65.1K.
  • Foghorn Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3484 holding.
  • Nuveen first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Nuveen's Foghorn Therapeutics position peaked at $1.52M in Q1 2022.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.